Ho Wah Genting Berhad’s Joint Venture Partner, Ebi obtained protocol approval From FDA registered IRB to conduct COVID-19 research study
2020-10-14 19:50:32
KUALA LUMPUR, 14 October 2020 – Ho Wah Genting Berhad’s (“HWGB” or the “Company”) (Bursa Stock Code:9601) wholly-owned subsidiary, HWGB Biotech Sdn Bhd’s (“HWGB Biotech”) [formerly known as HWG Consortium Sdn Bhd] joint venture partner, US-based E-MO Biology Inc (“EBI”), has obtained protocol approval from Advarra Inc., an institutional review board (“IRB”) to conduct a research study on the immune response induced by poliovirus vaccine booster that cross-reacts with Severe Acute Respiratory Syndrome Coronavirus.
Advarra Inc. is an institutional review board (“IRB”) registered with FDA. Under FDA regulations, an IRB is an appropriately constituted group that has been formally designated to review and monitor biomedical research involving human subjects. In accordance with FDA regulations, an IRB has the authority to approve, require modifications in (to secure approval), or disapprove research. This group review serves an important role in the protection of the rights and welfare of human research subjects.
Chief Executive Officer of HWGB, Dato’ Aaron Lim said: “This is great news indeed as our COVID-19 vaccine candidate is another step closer to undergoing the final phase of the clinical trial needed for it to be safe for human use”.
“We are following closely on the developments in this crucial venture of our healthcare business as we want to do our bit in helping to combat the virus that has affected the health of so many, including their livelihoods and income,” Dato’ Aaron Lim said.
ABOUT HO WAH GENTING BERHAD
Ho Wah Genting Berhad (“HWGB” or the “Company”) is principally engaged in investment holdings and the provision of management services to its subsidiaries. The Company had on 30 June 2020 diversified its existing businesses to include healthcare related industry which mainly involved in Health Supplement, Biotechnology and Health Technology. In addition, the Company and its subsidiaries (“HWGB Group” or the “Group”) are also engaging in the businesses of Investment holdings; manufacturing of wires and cables and moulded power supply cord sets and cable assemblies for electrical and electronic devices and equipment; Trading of wires and cables; and travel agent and tour related services.
For more information on about HWGB Biotech, follow us on https://hwgbbiotech.com, http://subscription.hwgbbiotech.com, https://www.facebook.com/hwgbbiotech, https://www.linkedin.com/company/hwgbbiotech and https://t.me/hwgbbiotech to view the latest updates about our company ventures in the healthcare industry.
ABOUT E-MO BIOLOGY INC.
E-MO Biology Inc (“EBI”) was incorporated in the state of California in the United States of America on 24 May 2020. It is principally involved in conducting biology research and development activities and is the sponsor of a study which indicates booster polio vaccine to reduce Covid-19 SARS-COV-2 infection and severity.
EBI is founded by Prof. Xie QiYi, who serves as its Managing Director of EBI. He has over 30 years of experiences in areas of public health and infection disease control. He was also involved in the development of medical and diagnostic devices, with focus on Quality, Regulatory and Clinical Affairs for quality systems.
KUALA LUMPUR, 14 October 2020 – Ho Wah Genting Berhad’s (“HWGB” or the “Company”) (Bursa Stock Code:9601) wholly-owned subsidiary, HWGB Biotech Sdn Bhd’s (“HWGB Biotech”) [formerly known as HWG Consortium Sdn Bhd] joint venture partner, US-based E-MO Biology Inc (“EBI”), has obtained protocol approval from Advarra Inc., an institutional review board (“IRB”) to conduct a research study on the immune response induced by poliovirus vaccine booster that cross-reacts with Severe Acute Respiratory Syndrome Coronavirus.
Advarra Inc. is an institutional review board (“IRB”) registered with FDA. Under FDA regulations, an IRB is an appropriately constituted group that has been formally designated to review and monitor biomedical research involving human subjects. In accordance with FDA regulations, an IRB has the authority to approve, require modifications in (to secure approval), or disapprove research. This group review serves an important role in the protection of the rights and welfare of human research subjects.
Chief Executive Officer of HWGB, Dato’ Aaron Lim said: “This is great news indeed as our COVID-19 vaccine candidate is another step closer to undergoing the final phase of the clinical trial needed for it to be safe for human use”.
“We are following closely on the developments in this crucial venture of our healthcare business as we want to do our bit in helping to combat the virus that has affected the health of so many, including their livelihoods and income,” Dato’ Aaron Lim said.
E-MO Biology Inc (“EBI”) was incorporated in the state of California in the United States of America on 24 May 2020. It is principally involved in conducting biology research and development activities and is the sponsor of a study which indicates booster polio vaccine to reduce Covid-19 SARS-COV-2 infection and severity.
EBI is founded by Prof. Xie QiYi, who serves as its Managing Director of EBI. He has over 30 years of experiences in areas of public health and infection disease control. He was also involved in the development of medical and diagnostic devices, with focus on Quality, Regulatory and Clinical Affairs for quality systems.